Development of MenFive®, an affordable pentavalent meningococcal conjugate vaccine (ACYWX) for Africa and beyond
- PMID: 40968077
- PMCID: PMC12452429
- DOI: 10.1080/21645515.2025.2559506
Development of MenFive®, an affordable pentavalent meningococcal conjugate vaccine (ACYWX) for Africa and beyond
Abstract
Wide use of the groundbreaking vaccine MenAfriVac® has eliminated serogroup A meningococcal meningitis in the African meningitis belt and paved the way for elimination of all meningococcal disease outbreaks with the development, licensure, and introduction of an affordable multivalent conjugate vaccine that covers all disease-causing serogroups in the region. With supportive funding from the UK government's Foreign, Commonwealth & Development Office, the global public health nonprofit PATH, and the Serum Institute of India Pvt. Ltd. extended their collaboration on MenAfriVac to develop, license, and World Health Organization prequalify MenFive®, an ACWYX meningococcal conjugate vaccine. The task of developing a low-priced, strongly immunogenic, pentavalent meningococcal conjugate vaccine required multiple collaborators and complex coordination, with numerous challenges and lessons learned. Importantly, MenFive has the potential to eliminate meningococcal disease outbreaks-not only in Africa (with recent deployment of outbreak response during the 2024 and 2025 meningitis seasons) but also in other regions of the world.
Keywords: African meningitis belt; Meningococcus; conjugate vaccine; meningitis; vaccination.
Conflict of interest statement
Drs. Kulkarni, Pisal, LaForce, and Dhere are or were formerly employed by SIIPL, the manufacturer of MenFive. Dr. Alderson, Ms. Regan, Mr. Martellet, and Dr. Hosken are or were employed by PATH, a collaborator on MenFive’s development. Drs. Pisal and Dhere are co-inventors on 20 patent applications emerging out of in-house MenFive research at SIIPL.
References
-
- GBD 2019 Meningitis Antimicrobial Resistance Collaborators . Global, regional, and national burden of meningitis and its aetiologies, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2023;22(8):685–13. doi: 10.1016/S1474-4422(23)00195-3. - DOI - PMC - PubMed
-
- Mazamay S, Guégan JF, Diallo N, Bompangue D, Bokabo E, Muyembe J, Taty N, Vita TP, Broutin H.. An overview of bacterial meningitis epidemics in Africa from 1928 to 2018 with a focus on epidemics “outside-the-belt”. BMC Infect Dis. 2021;21(1):1027. doi: 10.1186/s12879-021-06724-1. - DOI - PMC - PubMed
-
- World Health Organization . Weekly epidemiological record (WER). 2022. Sep 2 [accessed 2025 Aug]. https://reliefweb.int/report/world/weekly-epidemiological-record-wer-2-s....
-
- World Health Organization . Meningitis weekly bulletin. 2024. Apr 15–21 [accessed 2024 Jul]. https://cdn.who.int/media/docs/default-source/documents/emergencies/heal....
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical